Tiotropium
Treatment for Chronic Bronchitis
Typical Dosage: 18 mcg once daily (HandiHaler) or 2.5 mcg (Respimat) once daily
Effectiveness
70%
Safety Score
60%
Clinical Trials
11
Participants
60K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
60
DangerousModerateSafe
Treatment Details
Dosage Range
18 mcg once daily (HandiHaler) or 2.5 mcg (Respimat) once daily
Time to Effect
Within 30 minutes
Treatment Duration
Lifetime
Evidence Quality
HIGHNumber Needed to Treat (NNT)
13(Treat 13 patients to see 1 additional successful outcome)
Confidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$4,500
Monitoring:$600
Side Effect Mgmt:$100
Total Annual:$5,200
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENTICER
$35,000/QALY
QALYs Gained
0.08
Outcome-Based Costs
Cost per Responder
$8,000
Cost per Remission
$104,000
Tiotropium Outcomes
for Chronic Bronchitis
Efficacy Outcomes
Overall Effectiveness
+70%
Response Rate
+65%
Remission Rate
+5%
Common Side Effects
Dry mouth
+13%
Upper respiratory tract infection
+5%
Pharyngitis
+3%
Cough
+2.5%
Dyspepsia
+1.5%
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov
Completed Clinical Trials
10 completed trials for Tiotropium in Chronic Bronchitis
The Effects of Tiotropium on the Cough Reflex in Patients With Chronic Obstructive Pulmonary Disease (COPD)
NCT00870896COMPLETEDEARLY_PHASE1
5 participants
INTERVENTIONAL
Tampa, United States +1 more
Started: Feb 1, 2008
Add-on Effects of Tiotropium Over Formoterol in Exercise Tolerance on Chronic Obstructive Pulmonary Disease Patients
NCT00680056COMPLETEDPHASE4
33 participants
INTERVENTIONAL
São Paulo, Brazil
Started: Nov 1, 2007
Efficacy Safety Study of Arformoterol/Tiotropium Combination Versus Either Therapy Alone in Chronic Obstructive Pulmonary Disease (COPD)
NCT00424528COMPLETEDPHASE4
235 participants
INTERVENTIONAL
Jasper, United States +27 more
Started: Dec 1, 2006
Pharmacokinetic Study in Elderly Patients With Chronic Obstructive Bronchitis (COPD)
NCT02172326COMPLETEDPHASE3
29 participants
INTERVENTIONAL
Started: Feb 1, 1998
GSK573719 Dose Ranging Study in Chronic Obstructive Pulmonary Disease
NCT00950807COMPLETEDPHASE2
176 participants
INTERVENTIONAL
Phoenix, United States +18 more
Started: Sep 1, 2009
Efficacy and Safety of Tiotropium Compared to Salmeterol and Placebo in Patients With Chronic Obstructive Bronchitis (COPD)
NCT02173691COMPLETEDPHASE3
584 participants
INTERVENTIONAL
Started: Feb 1, 1999
A Randomized, Double Blind, Placebo Controlled, Incomplete Block, Crossover, Dose Ranging Study to Evaluate the Dose Response of GSK573719 Administered Once or Twice Daily Over 7 Days in Patients With Chronic Obstructive Pulmonary Disease (COPD)
NCT01372410COMPLETEDPHASE2
163 participants
INTERVENTIONAL
Costa Mesa, United States +12 more
Started: Jul 1, 2011
Long-term Use of Spiolto Respimat in Japanese Patients With Chronic Obstructive Pulmonary Disease
NCT02850978COMPLETED
1.33K participants
OBSERVATIONAL
Multiple Locations, Japan
Started: Aug 23, 2016
A Dose Range Finding Study to Evaluate the Efficacy and Safety of AZD9668 Administered Orally at Three Dose Levels to Patients With Chronic Obstructive Pulmonary Disease (COPD) on Treatment With Tiotropium
NCT00949975COMPLETEDPHASE2
838 participants
INTERVENTIONAL
Fullerton, United States +104 more
Started: Jul 1, 2009
A Study to Assess the Safety and Efficacy of Different AD 237 Doses in Adults With COPD
NCT00242333COMPLETEDPHASE2
300 participants
INTERVENTIONAL
Plovdiv, Bulgaria +32 more
Started: Oct 1, 2005